Menu UF Health Home Menu
 

Regeneron R1033 (R1033-HV-1223), A randomized, double-blind, placebo-controlled, parallel group, multicenter study of the effects of repeated doses of subcutaneous REGN1033 treatment with and without exercise, on safety, body composition, muscle strength and stair climb power in male and female subjects aged 60 and older.

Published: November 19th, 2013

Category: Projects

PI: Pahor, Marco, MD
PI: Manini, Todd, Ph.D.
Funding Agency: Regeneron Pharmaceuticals, Inc.
Start Date: Jul 1, 2013
End Date: Jun 30, 2014
Core Support: Clinical Translational Research Core